Edition:
United States

Ironwood Pharmaceuticals Inc (IRWD.OQ)

IRWD.OQ on NASDAQ Stock Exchange Global Select Market

15.84USD
22 Sep 2017
Change (% chg)

$0.32 (+2.06%)
Prev Close
$15.52
Open
$15.55
Day's High
$15.86
Day's Low
$15.49
Volume
294,427
Avg. Vol
348,934
52-wk High
$19.94
52-wk Low
$12.48

Chart for

About

Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease... (more)

Overall

Beta: 1.46
Market Cap(Mil.): $2,369.54
Shares Outstanding(Mil.): 149.59
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 80.89 16.34
EPS (TTM): -- -- --
ROI: -- 3.08 14.66
ROE: -- 4.82 14.00

BRIEF-Ironwood Pharma says CFO Tom Graney will leave company

* Ironwood Pharmaceuticals Inc- Tom Graney, chief financial officer will leave company

Sep 06 2017

FDA approves Ironwood Pharma's gout drug

Aug 21 Ironwood Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration (FDA) approved its oral drug to treat a condition associated with gout.

Aug 21 2017

BRIEF-Ironwood Pharma announces FDA approval of Duzallo to treat hyperuricemia in patients with uncontrolled gout

* Ironwood Pharmaceuticals announces FDA approval of Duzallo (Lesinurad And Allopurinol) for the treatment of hyperuricemia in patients with uncontrolled gout

Aug 21 2017

BRIEF-Ironwood Pharmaceuticals Q2 loss per share $0.30

* Ironwood Pharmaceuticals provides second quarter 2017 investor update

Aug 03 2017

Ironwood reflux drug appears effective, safe in midstage trial

Ironwood Pharmaceuticals Inc said on Thursday its potential blockbuster drug for gastroesophageal reflux disease (GERD) not controlled by current medicines significantly reduced heartburn severity and regurgitation frequency, meeting the main goals of a midstage trial.

Jul 20 2017

Ironwood reflux drug appears effective, safe in midstage trial

July 20 Ironwood Pharmaceuticals Inc said on Thursday its potential blockbuster drug for gastroesophageal reflux disease (GERD) not controlled by current medicines significantly reduced heartburn severity and regurgitation frequency, meeting the main goals of a midstage trial.

Jul 20 2017

BRIEF-Ironwood Pharmaceuticals reports Q1 loss per share of $0.36

* Ironwood pharmaceuticals provides first quarter 2017 investor update

May 08 2017

Earnings vs. Estimates